Overview

* Prestige Q2 revenue of $274.1 mln beats analyst expectations despite a 3.4% decline yr/yr

* Adjusted EPS of $1.07 for Q2 beats analyst estimates

* Company repurchased 1.1 mln shares in Q2, enhancing shareholder value

Outlook

* Prestige maintains fiscal 2026 revenue outlook at $1,100 mln to $1,115 mln

* Company tightens fiscal 2026 adjusted EPS outlook to $4.54 to $4.58

* Prestige expects fiscal 2026 free cash flow of $245 mln or more

Result Drivers

* SUPPLY TIMING - Clear Eyes supply timing and retailer order timing helped surpass sales and earnings expectations

* LIMITED SUPPLY - Revenue decline driven by limited ability to supply demand for Clear Eyes in Ear & Eye Care category

* BRAND-BUILDING - Focus on brand-building and maintaining financial profile contributed to robust free cash flow

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $274.11 $257.13

Revenue mln mln (7

Analysts

)

Q2 Beat $1.07 $0.97 (7

Adjusted Analysts

EPS )

Q2 Net $42.21

Income mln

Q2 Gross $151.58

Profit mln

Q2 $71.91

Operatin mln

g

Expenses

Q2 $79.67

Operatin mln

g Income

Q2 $69.13

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc ( PBH ) is $80.00, about 25.2% above its November 5 closing price of $59.83

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)